PeopleofSuperintelligence

Builder

Michael Nally

Also known as Mike Nally, Michael T. Nally

Mike Nally is chief executive of Generate:Biomedicines, a machine learning protein therapy company. He joined Flagship Pioneering as CEO-Partner in 2021 after nearly 18 years at Merck, where he most recently served as executive vice president and chief marketing officer of its Human Health division. Generate raised a $370 million Series B in 2021 and a $273 million Series C in 2023. The company announced a multi-target collaboration with Novartis in 2024 and completed its IPO in 2026, raising about $400 million.

Now at
Generate:Biomedicines

Timeline

  1. 2003–2021

    Nearly 18 years at Merck

    He joins Merck in 2003 and spends nearly 18 years there, most recently as executive vice president and chief marketing officer of its Human Health division.

  2. March 2021

    Joining Flagship as CEO-Partner

    Flagship Pioneering names him CEO-Partner in March 2021. He also takes over as CEO of Generate Biomedicines, a machine learning protein therapy company.

  3. November 2021

    A $370 million Series B

    Generate Biomedicines announces a $370 million Series B round for protein-based drugs in November 2021.

  4. January 2022

    A research deal with Amgen

    Amgen and Generate Biomedicines announce a research collaboration to discover and create protein therapeutics for five clinical targets in January 2022.

  5. September 2023

    A $273 million Series C

    The company announces the close of a $273 million Series C in September 2023 to advance its generative AI pipeline.

  6. September 2024

    A Novartis collaboration

    Novartis and Generate Biomedicines announce a multi-target collaboration to discover and develop protein therapeutics with generative AI in September 2024.

  7. 2026

    An IPO raising about $400 million

    Generate completes its IPO in 2026, raising approximately $400 million to advance its platform and pipeline.

  8. Since 2021

    Chief executive since 2021

    He is chief executive of Generate:Biomedicines, a role he has held since 2021.

Sources and credits

Photo: We have no published photo of Michael Nally yet. Send us a free-licensed photo.

  1. Merck’s President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief Commercial Officer and Michael Nally Named Chief Marketing Officer merck.com. Checked 15 October 2026.
  2. Michael Nally | Flagship Pioneering flagshippioneering.com. Checked 15 October 2026.
  3. Flagship Pioneering Expands Leadership Team with Appointment of Michael T. Nally as CEO-Partner flagshippioneering.com. Checked 15 October 2026.
  4. Former Merck Exec Joins Flagship to Helm AI Startup Generate Biomedicines biospace.com. Checked 15 October 2026.
  5. Generate Biomedicines raises $370M Series B with a focus on protein-based drugs techcrunch.com. Checked 15 October 2026.
  6. Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement amgen.com. Checked 15 October 2026.
  7. Generate:Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics generatebiomedicines.com. Checked 15 October 2026.
  8. Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI generatebiomedicines.com. Checked 15 October 2026.
  9. AI firm Generate signs $1bn discovery deal with Novartis pharmaphorum.com. Checked 15 October 2026.
  10. Leadership Team - Generate:Biomedicines investors.generatebiomedicines.com. Checked 15 October 2026.